AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9853771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ursodeoxycholic acid and S-adenosylmethionine
Number of subjects: 32
Study 9853771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin)
Number of subjects: 32
Study 7859801 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily for 2 weeks)
Number of subjects: 0
Study 7859801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 0
Study 2735626 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 250 mg orally every 4 hours
Number of subjects: 41
Study 2735626 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 0.5 mg/kg body weight intravenously every 4 hours
Number of subjects: 41
Study 2735626 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 2.5 mg/kg intravenously every 4 hours
Number of subjects: 41
Study 2735626 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 41
Study 2735626 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including zidovudine and placebo)
Number of subjects: 41
Study 31788741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance (n=19)
Number of subjects: 85
Study 31788741 — intervention group
Group type: COMPARATOR
Intervention: Observation (n=21)
Number of subjects: 85
Study 31788741 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (VMP)
Number of subjects: 85
Study 31670026 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-based drama intervention
Number of subjects: 26
Study 31670026 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 26
Study 28129949 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message intervention (daily reminders to monitor RMC)
Number of subjects: 244
Study 28129949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS messages)
Number of subjects: 244
Study 26596540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for chest pain (CBT‐CP)
Number of subjects: 126
Study 26596540 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 126
Study 24334181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine (TDF/FTC)
Number of subjects: 1813
Study 24334181 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine (ABC/3TC)
Number of subjects: 1813
Study 24334181 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 1813
Study 24334181 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 1813
Study 24334181 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1813
Study 21704807 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiband mucosectomy (MBM)
Number of subjects: 84
Study 21704807 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic resection-cap (ER-cap)
Number of subjects: 84
Study 19880935 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based treatment with therapist guidance and online group discussions
Number of subjects: 235
Study 19880935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure bibliotherapy
Number of subjects: 235
Study 19880935 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 235
Study 16830792 — intervention group
Group type: COMPARATOR
Intervention: MMP-9 levels and activity in decompensated MI patients (group B)
Number of subjects: 55
Study 16830792 — intervention group
Group type: COMPARATOR
Intervention: MMP-2 levels and activity in decompensated MI patients (group B)
Number of subjects: 55
Study 14553874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0
Study 14553874 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty with primary stenting
Number of subjects: 0
Study 11120521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestational diabetes mellitus requiring insulin therapy
Number of subjects: 1220
Study 11120521 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypertension
Number of subjects: 1220
Study 11120521 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 1220
Study 10086081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX)
Number of subjects: 87
Study 10086081 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 87
Study 8317684 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg
Number of subjects: 40
Study 8317684 — intervention group
Group type: COMPARATOR
Intervention: ketamine-racemat 2 mg/kg
Number of subjects: 40
Study 3743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg/day
Number of subjects: 6
Study 3743626 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.75 mg i.v. with cimetidine
Number of subjects: 6
Study 30340182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap (120-min polysomnographically monitored sleep opportunity), N=17
Number of subjects: 32
Study 30340182 — intervention group
Group type: COMPARATOR
Intervention: Wake (wakefulness), N=15
Number of subjects: 32
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leptin
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline leptin
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline adiponectin
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tumor necrosis factor α (TNF‐α)
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline TNF‐α
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C‐reactive protein (CRP)
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline CRP
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline monocyte chemoattractant protein‐1
Number of subjects: 2330
Study 27289411 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline IL‐6
Number of subjects: 2330
Study 25103183 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop My Smoking (SMS) USA mHealth program
Number of subjects: 164
Study 23227470 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 15
Study 23227470 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex- and age-matched medical ward patients)
Number of subjects: 15
Study 20484759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness training (F)
Number of subjects: 128
Study 20484759 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (W)
Number of subjects: 128
Study 20484759 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 128
Study 17631387 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm, lubricant gel, and condoms
Number of subjects: 4948
Study 17631387 — intervention group
Group type: COMPARATOR
Intervention: Condoms alone
Number of subjects: 4948
Study 16044144 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell-depleted (TCD) donor marrow
Number of subjects: 410
Study 16044144 — intervention group
Group type: COMPARATOR
Intervention: Unmanipulated donor marrow with methotrexate and cyclosporine (M/C)
Number of subjects: 410
Study 12401617 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg 1 h before surgery
Number of subjects: 0
Study 12401617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10542928 — intervention group
Group type: EXPERIMENTAL
Intervention: External local infiltration anaesthesia
Number of subjects: 54
Study 10542928 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA cream
Number of subjects: 54
Study 10542928 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical AMETOP gel
Number of subjects: 54
Study 10542928 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intranasal cocaine (administered to all groups)
Number of subjects: 54
Study 7598276 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II scoring for patients requiring prolonged ICU stay (14-84 days)
Number of subjects: 43
Study 7598276 — intervention group
Group type: COMPARATOR
Intervention: APACHE II scoring for control group (ICU stay of 48 hours or less)
Number of subjects: 43
Study 2358837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide 4.5 to 5.25 g/m2, etoposide 750 to 1,200 mg/m2, and cisplatin 120 to 180 mg/m2 (CVP)
Number of subjects: 58
Study 2358837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide, etoposide, and cisplatin
Number of subjects: 58
Study 778990 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg four times a day
Number of subjects: 30
Study 778990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30566415 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (0.25, 1, 2, 4 mg)
Number of subjects: 0
Study 30566415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30566415 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (flexible-dose 1-4 mg/d)
Number of subjects: 0
Study 30566415 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study 28272299 — intervention group
Group type: COMPARATOR
Intervention: Genetic group
Number of subjects: 0
Study 28272299 — intervention group
Group type: COMPARATOR
Intervention: Non-Genetic group
Number of subjects: 0
Study 28272299 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study 25923818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided unilateral TAP block with 20 mL 7.5 mg/mL ropivacaine
Number of subjects: 16
Study 23670744 — intervention group
Group type: EXPERIMENTAL
Intervention: BiCision
Number of subjects: 30
Study 23670744 — intervention group
Group type: COMPARATOR
Intervention: UltraCision
Number of subjects: 30
Study 21586838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg in 0.05 ml) monthly for 3 months
Number of subjects: 104
Study 21586838 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (1.25 mg in 0.05 ml) monthly for 3 months
Number of subjects: 104
Study 21586838 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ranibizumab and bevacizumab
Number of subjects: 104
Study 18298242 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session motivational enhancement intervention
Number of subjects: 220
Study 18298242 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 220
Study 16781216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6500
Study 16781216 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6500
Study 12669753 — intervention group
Group type: EXPERIMENTAL
Intervention: First-phoneme irregular word fillers (e.g., CHEF)
Number of subjects: 0
Study 12669753 — intervention group
Group type: COMPARATOR
Intervention: Third-phoneme irregular word fillers (e.g., GLOW)
Number of subjects: 0
Study 10731382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (Group 1, n = 58) for 8 weeks (24 sessions)
Number of subjects: 122
Study 10731382 — intervention group
Group type: COMPARATOR
Intervention: Normal daily physical activity (Group 2, n = 64)
Number of subjects: 122
Study 9042560 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40mg once daily for 21 days
Number of subjects: 179
Study 9042560 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 21 days
Number of subjects: 179
Study 1331558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 30 micrograms.kg‐1 (group F30)
Number of subjects: 25
Study 1331558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 75 micrograms.kg‐1 (group F75)
Number of subjects: 25
Study 1331558 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0.25 mg.kg‐1 and fentanyl 5 micrograms.kg‐1 (group N)
Number of subjects: 25
Study 3901663 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose regimen of acetylsalicylic acid
Number of subjects: 8
Study 3901663 — intervention group
Group type: COMPARATOR
Intervention: 3-dose regimen of acetylsalicylic acid
Number of subjects: 8
Study 3901663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2-dose and 3-dose regimens of acetylsalicylic acid
Number of subjects: 8
Study 31211964 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 364
Study 31211964 — intervention group
Group type: COMPARATOR
Intervention: Sacral neuromodulation
Number of subjects: 364
Study 31211964 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (subgroup with Vaizey score ≥12)
Number of subjects: 364
Study 31211964 — intervention group
Group type: COMPARATOR
Intervention: Sacral neuromodulation (subgroup with Vaizey score ≥12)
Number of subjects: 364
Study 29792728 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bolus DECT
Number of subjects: 118
Study 29792728 — intervention group
Group type: COMPARATOR
Intervention: Triple-phase MDCT
Number of subjects: 118
Study 26727506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trans-resveratrol (450 mg/d)
Number of subjects: 64
Study 26727506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose trans-resveratrol (150 mg/d)
Number of subjects: 64
Study 26727506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24183737 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of antibiotic (1g of amoxicillin); no postoperative antibiotics.
Number of subjects: 80
Study 24183737 — intervention group
Group type: COMPARATOR
Intervention: Preoperative dose of antibiotic (1g of amoxicillin) followed by a 3-day postoperative course.
Number of subjects: 80
Study 22160483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 519
Study 22160483 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 519
Study 21198221 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatively set goals
Number of subjects: 126
Study 21198221 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned goals
Number of subjects: 126
Study 21198221 — intervention group
Group type: COMPARATOR
Intervention: No goal condition
Number of subjects: 126
Study 17474873 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Mediterranean diet for 6 months
Number of subjects: 115
Study 17474873 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (Control)
Number of subjects: 115
Study 12971031 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with 12 ounces of water
Number of subjects: 14
Study 12971031 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with juice and cereal
Number of subjects: 14
Study 12971031 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with juice and cereal with milk
Number of subjects: 14
Study 12971031 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin administered with juice and cereal without milk
Number of subjects: 14
Study 11039508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFX) 2,000 mg/m2 IV infusion days 1 to 3; 2-mercaptoethanesulfonic acid sodium salt (mesna) 400 mg/m2 IV bolus H 0 and 4, 800 mg/m2 by mouth H 8, days 1 to 3; Vinorelbine (VNB) 25 mg/m2 IV infusion days 1 and 8; Cisplatin (CDDP) 75 mg/m2 IV day 3, repeated every 28 days for a total of three courses
Number of subjects: 40
Study 9322500 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.14 mg.kg‐1.day‐1), oral glutamine (0.63 g.kg‐1.day‐1), and high carbohydrate-low fat diet for 21 days
Number of subjects: 8
Study 9322500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1436129 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 12
Study 1436129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 12
Study 1436129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3467504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 100
Study 3467504 — intervention group
Group type: COMPARATOR
Intervention: Dye laser iridotomy
Number of subjects: 100
Study 31230661 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopic surveillance
Number of subjects: 125
Study 31230661 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap testing
Number of subjects: 125
Study 31230661 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 125
Study 30419961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of conventional medicine and Traditional Chinese Medicine (TCM), administered twice daily for 28 days.
Number of subjects: 198
Study 30419961 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine alone (control group).
Number of subjects: 198
Study 26880794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam
Number of subjects: 67
Study 26880794 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 67
Study 25292072 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 80
Study 25292072 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 80
Study 23019943 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy combined with Kanglaite Injection (KI) at 100 mL/d for 21 days, two cycles with one week interval.
Number of subjects: 50
Study 23019943 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and concurrent 3D‐CRT (Control group).
Number of subjects: 50
Study 20110554 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 961
Study 20110554 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 961
Study 20110554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 961
Study 17651563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inanimate box trainer (LTS 2000) for 10 sessions (Group A)
Number of subjects: 32
Study 17651563 — intervention group
Group type: COMPARATOR
Intervention: Inanimate box trainer (LTS 2000) and virtual reality trainer (MIST-VR) for 10 sessions (Group B)
Number of subjects: 32
Study 16401690 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 0
Study 16401690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14693180 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (2 ng/kg)
Number of subjects: 30
Study 14693180 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (ex vivo incubation)
Number of subjects: 30
Study 14693180 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (2-4 h after infusion)
Number of subjects: 30
Study 14693180 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (24 h after challenge)
Number of subjects: 30
Study 11339569 — intervention group
Group type: EXPERIMENTAL
Intervention: Telediagnostic procedures using digital images of cytological slides
Number of subjects: 54
Study 9240631 — intervention group
Group type: EXPERIMENTAL
Intervention: Register-based definition of CHD including all CHD deaths and hospitalizations with the ICD-8 code 410
Number of subjects: 0
Study 9240631 — intervention group
Group type: EXPERIMENTAL
Intervention: HHS results
Number of subjects: 0
Study 9240631 — intervention group
Group type: EXPERIMENTAL
Intervention: Wider definition of CHD including ICD-8 and ICD-9 codes 410-414
Number of subjects: 0
Study 9240631 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite AMI as a single definition of CHD
Number of subjects: 0
Study 8238173 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol, 200 mg/day for three menstrual cycles (n = 19)
Number of subjects: 57
Study 8238173 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose danazol regimen (200 mg/day for one cycle, 100 mg/day for one cycle, and 50 mg/day for one cycle) (n = 19)
Number of subjects: 57
Study 8238173 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone, 5 mg three times daily on days 19 through 26 of the cycle for three consecutive cycles (n = 19)
Number of subjects: 57
Study 3086204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin plus nitroglycerin
Number of subjects: 57
Study 3086204 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin alone
Number of subjects: 57
Study 31342246 — intervention group
Group type: EXPERIMENTAL
Intervention: On-clamp RAPN
Number of subjects: 302
Study 31342246 — intervention group
Group type: COMPARATOR
Intervention: Off-clamp RAPN
Number of subjects: 302
Study 28872404 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (lateral retinacular release and medial retinacular repair)
Number of subjects: 3
Study 28872404 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (patellar bracing and quadriceps strengthening)
Number of subjects: 3
Study 26701796 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) containing 843 mg (‐)‐epigallocatechin‐3‐gallate
Number of subjects: 121
Study 26701796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 26701796 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE)
Number of subjects: 121
Study 24491078 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate condition (10 weeks of web‐based self‐help via StopPulling.com)
Number of subjects: 60
Study 24491078 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2 (8 sessions of in‐person habit reversal training [HRT])
Number of subjects: 60
Study 24491078 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire stepped care program
Number of subjects: 60
Study 24491078 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) condition
Number of subjects: 60
Study 22790524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program focused on exercise and diet behavior
Number of subjects: 107